Cancer Chemotherapy Specific to Acidic Nests
Abstract
:1. Introduction
2. Metabolic Pathways Working under Acidic Conditions
3. Acidosis-Dependent Anti-Cancer Drugs
3.1. Statins
3.2. Cantharidin
3.3. Manumycin A
3.4. Ionomycin
3.5. Doxorubicin
4. Anti-Cancer Drugs Whose Efficacy Decreases at an Acidic pH
5. Proposal for Clinical Usage of Statins
6. Measurements of Acidity in Cancer Nests
7. Exploitation of Other Drugs Specific to Acidic Cancer Nests
8. Conclusions
Conflicts of Interest
References
- Meyer, K.A.; Kammerling, E.M.; Amtman, L.; Koller, M.; Hoffman, S.J. pH studies of malignant tissues in human beings. Cancer Res. 1948, 8, 513–518. [Google Scholar] [PubMed]
- Vaupel, P.; Kallinowski, F.; Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors. Cancer Res. 1989, 49, 6449–6465. [Google Scholar] [PubMed]
- Helmlinger, G.; Yuan, F.; Dellian, M.; Jain, R.K. Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation. Nat. Med. 1997, 3, 177–182. [Google Scholar] [CrossRef] [PubMed]
- Warburg, O. On the origin of cancer cells. Science 1956, 123, 309–314. [Google Scholar] [CrossRef] [PubMed]
- Vukovic, V.; Tannock, I.F. Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br. J. Cancer 1997, 75, 1167–1172. [Google Scholar] [CrossRef] [PubMed]
- Fukamachi, T.; Saito, H.; Kakegawa, T.; Kobayashi, H. Different proteins are phosphorylated under acidic environments in Jurkat cells. Immunol. Lett. 2002, 82, 155–158. [Google Scholar] [CrossRef]
- Sun, Y.; Fukamachi, T.; Saito, H.; Kobayashi, H. Adenosine deamination increases the survival under acidic conditions in Escherichia coli. J. Appl. Microbiol. 2012, 112, 775–781. [Google Scholar] [CrossRef] [PubMed]
- Fukamachi, T.; Ikeda, S.; Wang, X.; Saito, H.; Tagawa, M.; Kobayashi, H. Gene expressions for signal transduction under acidic conditions. Genes 2013, 4, 65–85. [Google Scholar] [CrossRef] [PubMed]
- Lao, Q.; Fukamachi, T.; Saito, H.; Kuge, O.; Nishijima, M.; Kobayashi, H. Requirement of an IkappaB-beta COOH terminal region protein for acidic-adaptation in CHO cells. J. Cell. Physiol. 2006, 207, 238–243. [Google Scholar] [CrossRef] [PubMed]
- Lao, Q.; Kuge, O.; Fukamachi, T.; Kakegawa, T.; Saito, H.; Nishijima, M.; Kobayashi, H. An IkappaB-beta COOH terminal region protein is essential for the proliferation of CHO cells under acidic stress. J. Cell. Physiol. 2005, 203, 186–192. [Google Scholar] [CrossRef] [PubMed]
- Fukamachi, T.; Lao, Q.; Okamura, S.; Saito, H.; Kobayashi, H. CTIB (C-terminus protein of IκB-β): A novel factor required for acidic adaptation. Adv. Exp. Med. Biol. 2006, 584, 219–228. [Google Scholar] [PubMed]
- Som, A.; Bloch, S.; Ippolito, J.E.; Achilefu, S. Acidic extracellular pH of tumors induces octamer-binding transcription factor 4 expression in murine fibroblasts in vitro and in vivo. Sci. Rep. 2016, 6, 27803. [Google Scholar] [CrossRef] [PubMed]
- Hjelmeland, A.B.; Wu, Q.; Heddleston, J.M.; Choudhary, G.S.; MacSwords, J.; Lathia, J.D.; McLendon, R.; Lindner, D.; Sloan, A.; Rich, J.N. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ. 2011, 18, 829–840. [Google Scholar] [CrossRef] [PubMed]
- Fukamachi, T.; Chiba, Y.; Wang, X.; Saito, H.; Tagawa, M.; Kobayashi, H. Tumor specific low pH environments enhance the cytotoxicity of lovastatin and cantharidin. Cancer Lett. 2010, 297, 182–189. [Google Scholar] [CrossRef] [PubMed]
- Fukamachi, T.; Wang, X.; Mochizuki, Y.; Maruyama, C.; Saito, H.; Kobayashi, H. Acidic environments enhance the inhibitory effect of statins on proliferation of synovial cells. Int. Immunopharmacol. 2013, 17, 148–153. [Google Scholar] [CrossRef] [PubMed]
- Fukamachi, T.; Kobayashi, H.; Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan. Unpublished work. 2010.
- Takai, Y.; Sasaki, T.; Matozaki, T. Small GTP-binding proteins. Physiol. Rev. 2001, 81, 153–208. [Google Scholar] [PubMed]
- Palsuledesai, C.C.; Distefano, M.D. Protein prenylation: Enzymes, therapeutics, and biotechnology applications. ACS Chem. Biol. 2015, 10, 51–62. [Google Scholar] [CrossRef] [PubMed]
- Wang, G.S. Medical uses of mylabris in ancient China and recent studies. J. Ethnopharmacol. 1989, 26, 147–162. [Google Scholar] [CrossRef]
- Shao, H.; Hong, G.; Luo, X. Evaluation of sodium cantharidinate/vitamin B6 in the treatment of primary liver cancer. J. Cancer Res. Ther. 2014, 10 (Suppl. 1), 75–78. [Google Scholar] [PubMed]
- Wu, W.; Su, M.; Li, T.; Wu, K.; Wu, X.; Tang, Z. Cantharidin-induced liver injuries in mice and the protective effect of vitamin C supplementation. Int. Immunopharmacol. 2015, 28, 182–187. [Google Scholar] [CrossRef] [PubMed]
- Verma, A.K.; Prasad, S.B. Bioactive component, cantharidin from Mylabris cichorii and its antitumor activity against Ehrlich ascites carcinoma. Cell. Biol. Toxicol. 2012, 28, 133–147. [Google Scholar] [CrossRef] [PubMed]
- Li, C.C.; Yu, F.S.; Fan, M.J.; Chen, Y.Y.; Lien, J.C.; Chou, Y.C.; Lu, H.F.; Tang, N.Y.; Peng, S.F.; Huang, W.W.; et al. Anticancer effects of cantharidin in A431 human skin cancer (Epidermoid carcinoma) cells in vitro and in vivo. Environ. Toxicol. 2017, 32, 723–738. [Google Scholar] [CrossRef] [PubMed]
- Zhan, Y.P.; Huang, X.E.; Cao, J.; Lu, Y.Y.; Wu, X.Y.; Liu, J.; Xu, X.; Xu, L.; Xiang, J.; Ye, L.H. Clinical study on safety and efficacy of Qinin® (cantharidin sodium) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pac. J. Cancer Prev. 2012, 13, 4773–4776. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.; Huang, X.E.; Cao, J. Clinical study on safety of cantharidin sodium and shenmai injection combined with chemotherapy in treating patients with breast cancer postoperatively. Asian Pac. J. Cancer Prev. 2014, 15, 5597–5600. [Google Scholar] [CrossRef] [PubMed]
- Dorn, D.C.; Kou, C.A.; Png, K.J.; Moore, M.A. The effect of cantharidins on leukemic stem cells. Int. J. Cancer 2009, 124, 2186–2199. [Google Scholar] [CrossRef] [PubMed]
- Honkanen, R.E. Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett. 1993, 330, 283–286. [Google Scholar] [CrossRef]
- Solár, P.; Sačková, V.; Hrčková, G.; Demečková, V.; Kassayová, M.; Bojková, B.; Mudroňová, D.; Gancarčíková, S.; Jendželovský, R.; Fedoročko, P. Antitumor effect of the combination of manumycin A and Immodin is associated with antiplatelet activity and increased granulocyte tumor infiltration in a 4T1 breast tumor model. Oncol. Rep. 2017, 37, 368–378. [Google Scholar] [PubMed]
- Singha, P.K.; Pandeswara, S.; Venkatachalam, M.A.; Saikumar, P. Manumycin A inhibits triple-negative breast cancer growth through LC3-mediated cytoplasmic vacuolation death. Cell Death Dis. 2013, 4, e457. [Google Scholar] [CrossRef] [PubMed]
- Yin, M.Z.; Park, S.W.; Kang, T.W.; Kim, K.S.; Yoo, H.Y.; Lee, J.; Kim, S.J. Activation of K+ channel by 1-EBIO rescues the head and neck squamous cell carcinoma cells from Ca2+ ionophore-induced cell death. Korean J. Physiol. Pharmacol. 2016, 20, 25–33. [Google Scholar] [CrossRef] [PubMed]
- Ahmed, K.H.; Pelster, B. Interdependence of Ca2+ and proton movements in trout hepatocytes. J. Exp. Biol. 2007, 210, 3473–3483. [Google Scholar] [CrossRef] [PubMed]
- Sauvant, C.; Nowak, M.; Wirth, C.; Schneider, B.; Riemann, A.; Gekle, M.; Thews, O. Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38. Int. J. Cancer 2008, 123, 2532–2542. [Google Scholar] [CrossRef] [PubMed]
- Kawata, S.; Yamasaki, E.; Nagase, T.; Inui, Y.; Ito, N.; Matsuda, Y.; Inada, M.; Tamura, S.; Noda, S.; Imai, Y.; et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br. J. Cancer 2001, 84, 886–891. [Google Scholar] [CrossRef] [PubMed]
- Wang, A.; Wakelee, H.A.; Aragaki, A.K.; Tang, J.Y.; Kurian, A.W.; Manson, J.E.; Stefanick, M.L. Protective effects of statins in cancer: Should they be prescribed for high-risk patients? Curr. Atheroscler. Rep. 2016, 18, 72. [Google Scholar] [CrossRef] [PubMed]
- Chae, Y.K.; Yousaf, M.; Malecek, M.K.; Carneiro, B.; Chandra, S.; Kaplan, J.; Kalyan, A.; Sassano, A.; Platanias, L.C.; Giles, F. Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit? Discov. Med. 2015, 20, 413–427. [Google Scholar] [PubMed]
- Kretzer, I.F.; Maria, D.A.; Guido, M.C.; Contente, T.C.; Maranhão, R.C. Simvastatin increases the antineoplastic actions of paclitaxel carried in lipid nanoemulsions in melanoma-bearing mice. Int. J. Nanomed. 2016, 11, 885–904. [Google Scholar]
- Cho, S.J.; Kim, J.S.; Kim, J.M.; Lee, J.Y.; Jung, H.C.; Song, I.S. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int. J. Cancer 2008, 123, 951–957. [Google Scholar] [CrossRef] [PubMed]
- Wang, C.Y.; Shui, H.A.; Chang, T.C. In vivo evidence of duality effects for lovastatin in a nude mouse cancer model. Int. J. Cancer 2010, 126, 578–582. [Google Scholar] [CrossRef] [PubMed]
- Ajith, T.A.; Harikumar, K.B.; Thasna, H.; Sabu, M.C.; Babitha, N.V. Proapoptotic and antitumor activities of the HMG-CoA reductase inhibitor, lovastatin, against Dalton’s lymphoma ascites tumor in mice. Clin. Chim. Acta 2006, 366, 322–328. [Google Scholar] [CrossRef] [PubMed]
- Williams, A.B.; Li, L.; Nguyen, B.; Brown, P.; Levis, M.; Small, D. Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. Blood 2012, 120, 3069–3079. [Google Scholar] [CrossRef] [PubMed]
- Vintonenko, N.; Jais, J.P.; Kassis, N.; Abdelkarim, M.; Perret, G.Y.; Lecouvey, M.; Crepin, M.; Di Benedetto, M. Transcriptome analysis and in vivo activity of fluvastatin versus zoledronic acid in a murine breast cancer metastasis model. Mol. Pharmacol. 2012, 82, 521–528. [Google Scholar] [CrossRef] [PubMed]
- Ajith, T.A.; Anu, V.; Riji, T. Antitumor and apoptosis promoting properties of atorvastatin, an inhibitor of HMG-CoA reductase, against Dalton’s Lymphoma Ascites tumor in mice. J. Exp. Ther. Oncol. 2008, 7, 291–298. [Google Scholar] [PubMed]
- Wang, H.; Cui, X.X.; Goodin, S.; Ding, N.; Van Doren, J.; Du, Z1.; Huang, M.T.; Liu, Y.; Cheng, X.; Dipaola, R.S.; et al. Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib. Oncol. Rep. 2014, 31, 835–841. [Google Scholar] [PubMed]
- Jeon, C.Y.; Goodman, M.T.; Cook-Wiens, G.; Sundaram, V. Statin use and survival with early stage hepatocellular carcinoma. Cancer Epidemiol. Biomarkers Prev. 2016, 25, 686–692. [Google Scholar] [CrossRef] [PubMed]
- Bachy, E.; Estell, J.A.; Van de Neste, E.; Bouabdallah, R.; Bargay, J.; Delmer, A.; Gelas-Dore, B.; Gomes da Silva, M.; Fitoussi, O.; Belada, D.; et al. Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study. Am. J. Hematol. 2016, 91, 410–415. [Google Scholar] [CrossRef] [PubMed]
- Keskiväli, T.; Kujala, P.; Visakorpi, T.; Tammela, T.L.; Murtola, T.J. Statin use and risk of disease recurrence and death after radical prostatectomy. Prostate 2016, 76, 469–478. [Google Scholar] [CrossRef] [PubMed]
- Fukamachi, T.; Saito, H.; Kobayashi, H. Effect of simvastatin on immune cells under alkaline and acidic conditions. J. Cancer Sci. Ther. 2015, 7, 48–54. [Google Scholar] [CrossRef]
- Carter, A.A.; Gomes, T.; Camacho, X.; Juurlink, D.N.; Shah, B.R.; Mamdani, M.M. Risk of incident diabetes among patients treated with statins: Population based study. BMJ 2013, 346, f2610. [Google Scholar] [CrossRef] [PubMed]
- Taylor, F.; Huffman, M.D.; Macedo, A.F.; Moore, T.H.; Burke, M.; Davey Smith, G.; Ward, K.; Ebrahim, S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 2013, 1, CD004816. [Google Scholar]
- Welty, F.K. Hypobetalipoproteinemia and abetalipoproteinemia. Curr. Opin. Lipidol. 2014, 25, 161–168. [Google Scholar] [CrossRef] [PubMed]
- Anderson, M.; Moshnikova, A.; Engelman, D.M.; Reshetnyak, Y.K.; Andreev, O.A. Probe for the measurement of cell surface pH in vivo and ex vivo. Proc. Natl. Acad. Sci. USA 2016, 113, 8177–8181. [Google Scholar] [CrossRef] [PubMed]
- Moon, B.F.; Jones, K.M.; Chen, L.Q.; Liu, P.; Randtke, E.A.; Howison, C.M.; Pagel, M.D. A comparison of iopromide and iopamidol, two acidoCEST MRI contrast media that measure tumor extracellular pH. Contrast Media Mol. Imaging 2015, 10, 446–455. [Google Scholar] [CrossRef] [PubMed]
- Fukamachi, T.; Ikeda, S.; Saito, H.; Tagawa, M.; Kobayashi, H. Expression of acidosis-dependent genes in human cancer nests. Mol. Clin. Oncol. 2014, 2, 1160–1166. [Google Scholar] [CrossRef] [PubMed]
- Chen, B.; Liu, J.; Ho, T.T.; Ding, X.; Mo, Y.Y. ERK-mediated NF-κB activation through ASIC1 in response to acidosis. Oncogenesis 2016, 5, e279. [Google Scholar] [CrossRef] [PubMed]
Efficacy | Compounds |
---|---|
Higher at acidic pH | lovastatin, cantharidin manumycin A *, ionomycin ** |
Lower at acidic pH | aphidicolin, vinblastine sulfate, paclitaxel, aclarubicin, trichostatin A, 17-AAG |
No change at acidic pH | mitomycin C, bleomycin sulfate, methotrexate, daunorubicin, actinomycin D, camptothecin, etoposide, cytochalasin D, kenpaullone, cycloheximide, radicicol, cucurbitacin 1, hydroxyurea, doxorubicin |
Statins | Defined Daily Doses | Mouse Model | |
---|---|---|---|
Effective Dose | Cancers (in literature) | ||
Simvastatin | 30 mg | 50 mg/kg/day * | melanoma [36] |
50 mg/kg/day * | colon cancer [37] | ||
Lovastatin | 45 mg | 10 mg/kg/day * | thyroid cancer [38] |
16 mg/kg/day * | ascites tumor [39] | ||
Fluvastatin | 60 mg | 40 mg/kg/day * | leukemia [40] |
15 mg/kg/day ** | breast cancer [41] | ||
Atorvastatin | 20 mg | 16 mg/kg/day ** | ascites tumor [42] |
10 mg/kg/day ** | prostate cancer [43] |
© 2017 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kobayashi, H. Cancer Chemotherapy Specific to Acidic Nests. Cancers 2017, 9, 36. https://doi.org/10.3390/cancers9040036
Kobayashi H. Cancer Chemotherapy Specific to Acidic Nests. Cancers. 2017; 9(4):36. https://doi.org/10.3390/cancers9040036
Chicago/Turabian StyleKobayashi, Hiroshi. 2017. "Cancer Chemotherapy Specific to Acidic Nests" Cancers 9, no. 4: 36. https://doi.org/10.3390/cancers9040036